ERBB2 and lung carcinoma: To address HER2+ lung cancer, a biomimetic nanoplatform including Cisplatin-loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles and coating them with CAR-T cell-derived membranes from genetically engineered human Jurkat T cells, exhibiting effective tumor infiltration at the site of HER2+ lung cancer (107).